These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36140231)

  • 1. Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.
    Nagy T; Toth NM; Palmer E; Polivka L; Csoma B; Nagy A; Eszes N; Vincze K; Bárczi E; Bohács A; Tárnoki ÁD; Tárnoki DL; Nagy G; Kiss E; Maurovich-Horvát P; Müller V
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.
    Løkke A; Castello L; Pinheiro Martins P; Soulard S; Hilberg O
    Adv Ther; 2023 Dec; 40(12):5502-5518. PubMed ID: 37837527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
    Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
    Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease.
    Jang HJ; Woo A; Kim SY; Yong SH; Park Y; Chung K; Lee SH; Leem AY; Lee SH; Kim EY; Jung JY; Kang YA; Kim YS; Park MS
    Ann Med; 2023 Dec; 55(1):663-671. PubMed ID: 37074318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
    Petelytska L; Bonomi F; Cannistrà C; Fiorentini E; Peretti S; Torracchi S; Bernardini P; Coccia C; De Luca R; Economou A; Levani J; Matucci-Cerinic M; Distler O; Bruni C
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37940340
    [No Abstract]   [Full Text] [Related]  

  • 9. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
    Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
    Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial lung disease associated with systemic sclerosis (SSc-ILD).
    Cottin V; Brown KK
    Respir Res; 2019 Jan; 20(1):13. PubMed ID: 30658650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
    [No Abstract]   [Full Text] [Related]  

  • 17. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
    De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
    J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.